Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV

Business Wire June 23, 2016

Biotechs Are Ripping Following IPAB Ruling

Benzinga.com  June 22, 2016

6 Stocks Moving In Monday's After-Hours Session

Benzinga.com  June 20, 2016

Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV

Business Wire June 20, 2016

Covered Call reports for Gilead Sciences, Activision Blizzard, General Electric, Cisco Systems, and Merck & Company Incorporated include trade ideas that offer returns of 20% or more!

PR Newswire June 17, 2016

Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14

Business Wire June 13, 2016

Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10

Business Wire June 9, 2016

Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8

Business Wire June 7, 2016

BetterInvesting Top 100 Performance Topped S&P Benchmark for 5 Years Ended May 31

PR Newswire June 7, 2016

TD Ameritrade's IMX Growth Hits Record High In May: Check Out Clients' Picks & Pans

Benzinga.com  June 6, 2016

BetterInvesting Magazine Releases August Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use

PR Newswire June 3, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.

Business Wire May 27, 2016

LafargeHolcim réalise des émissions obligataires et finalise une offre de rachat

Business Wire May 27, 2016

LafargeHolcim Issues Medium Term Notes and Completes Repurchase Tender Offer

Business Wire May 27, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences Inc. - GILD

PR Newswire May 27, 2016

European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Business Wire May 27, 2016

Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy

Business Wire May 24, 2016

Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23

Business Wire May 20, 2016

Main Street's Index, the BetterInvesting Top 100, Increased 11.4 Percent Annually for the 5 Years Ended April 29

PR Newswire May 11, 2016

Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10

Business Wire May 9, 2016